24 May 2013
Keywords: medarex, up, 225m, diff, deal, merck, co
Article | 22 April 2009
Merck & Co and fellow USA-based firm Medarex have licensed an investigational, fully-human monoclonal antibody combination developed
to target and neutralize ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 April 2009
21 April 2009
23 May 2013
© 2013 thepharmaletter.com